Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection.
BA.5
IgA
IgG
Omicron
SARS-Cov-2
Translation to patients
breakthrough
mucosal immunity
neutralization
vaccine
variants
Journal
Med (New York, N.Y.)
ISSN: 2666-6340
Titre abrégé: Med
Pays: United States
ID NLM: 101769215
Informations de publication
Date de publication:
09 Dec 2022
09 Dec 2022
Historique:
received:
10
08
2022
revised:
09
09
2022
accepted:
28
09
2022
pubmed:
14
10
2022
medline:
15
12
2022
entrez:
13
10
2022
Statut:
ppublish
Résumé
Since early 2022, Omicron BA.1 has been eclipsed by BA.2, which was in turn outcompeted by BA.5, which displays enhanced antibody escape properties. Here, we evaluated the duration of the neutralizing antibody (Nab) response, up to 18 months after Pfizer BNT162b2 vaccination, in individuals with or without BA.1/BA.2 breakthrough infection. We measured neutralization of the ancestral D614G lineage, Delta, and Omicron BA.1, BA.2, and BA.5 variants in 300 sera and 35 nasal swabs from 27 individuals. Upon vaccination, serum Nab titers were decreased by 10-, 15-, and 25-fold for BA.1, BA.2, and BA.5, respectively, compared with D614G. We estimated that, after boosting, the duration of neutralization was markedly shortened from 11.5 months with D614G to 5.5 months with BA.5. After breakthrough, we observed a sharp increase of Nabs against Omicron subvariants, followed by a plateau and a slow decline after 5-6 months. In nasal swabs, infection, but not vaccination, triggered a strong immunoglobulin A (IgA) response and a detectable Omicron-neutralizing activity. BA.5 spread is partly due to abbreviated vaccine efficacy, particularly in individuals who were not infected with previous Omicron variants. Work in O.S.'s laboratory is funded by the Institut Pasteur, Urgence COVID-19 Fundraising Campaign of Institut Pasteur, Fondation pour la Recherche Médicale (FRM), ANRS, the Vaccine Research Institute (ANR-10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), ANR/FRM Flash Covid PROTEO-SARS-CoV-2, ANR Coronamito, and IDISCOVR, Laboratoire d'Excellence 'Integrative Biology of Emerging Infectious Diseases' (grant no. ANR-10-LABX-62-IBEID), HERA european funding and the NIH PICREID (grant no U01AI151758).
Sections du résumé
BACKGROUND
BACKGROUND
Since early 2022, Omicron BA.1 has been eclipsed by BA.2, which was in turn outcompeted by BA.5, which displays enhanced antibody escape properties.
METHODS
METHODS
Here, we evaluated the duration of the neutralizing antibody (Nab) response, up to 18 months after Pfizer BNT162b2 vaccination, in individuals with or without BA.1/BA.2 breakthrough infection. We measured neutralization of the ancestral D614G lineage, Delta, and Omicron BA.1, BA.2, and BA.5 variants in 300 sera and 35 nasal swabs from 27 individuals.
FINDINGS
RESULTS
Upon vaccination, serum Nab titers were decreased by 10-, 15-, and 25-fold for BA.1, BA.2, and BA.5, respectively, compared with D614G. We estimated that, after boosting, the duration of neutralization was markedly shortened from 11.5 months with D614G to 5.5 months with BA.5. After breakthrough, we observed a sharp increase of Nabs against Omicron subvariants, followed by a plateau and a slow decline after 5-6 months. In nasal swabs, infection, but not vaccination, triggered a strong immunoglobulin A (IgA) response and a detectable Omicron-neutralizing activity.
CONCLUSIONS
CONCLUSIONS
BA.5 spread is partly due to abbreviated vaccine efficacy, particularly in individuals who were not infected with previous Omicron variants.
FUNDING
BACKGROUND
Work in O.S.'s laboratory is funded by the Institut Pasteur, Urgence COVID-19 Fundraising Campaign of Institut Pasteur, Fondation pour la Recherche Médicale (FRM), ANRS, the Vaccine Research Institute (ANR-10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), ANR/FRM Flash Covid PROTEO-SARS-CoV-2, ANR Coronamito, and IDISCOVR, Laboratoire d'Excellence 'Integrative Biology of Emerging Infectious Diseases' (grant no. ANR-10-LABX-62-IBEID), HERA european funding and the NIH PICREID (grant no U01AI151758).
Identifiants
pubmed: 36228619
pii: S2666-6340(22)00411-1
doi: 10.1016/j.medj.2022.09.010
pmc: PMC9533668
pii:
doi:
Substances chimiques
BNT162 Vaccine
0
Antibodies, Neutralizing
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
838-847.e3Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare no competing interests.
Références
Cell. 2022 Jul 7;185(14):2422-2433.e13
pubmed: 35772405
N Engl J Med. 2022 Jun 30;386(26):2526-2528
pubmed: 35704428
Nat Med. 2021 May;27(5):917-924
pubmed: 33772244
N Engl J Med. 2022 Feb 10;386(6):599-601
pubmed: 35030645
Cell. 2022 Jul 7;185(14):2434-2451.e17
pubmed: 35764089
Cell. 2022 Feb 3;185(3):457-466.e4
pubmed: 34995482
Nature. 2022 Aug;608(7923):603-608
pubmed: 35790190
N Engl J Med. 2022 Jul 7;387(1):86-88
pubmed: 35731894
Med Sci Monit. 2022 Jul 01;28:e937676
pubmed: 35775166
Lancet Infect Dis. 2022 Oct 18;:
pubmed: 36270311
Nature. 2022 Jul;607(7917):128-134
pubmed: 35447027
Nat Med. 2022 Jun;28(6):1297-1302
pubmed: 35322239
Nature. 2021 Aug;596(7872):417-422
pubmed: 34192737
Nat Med. 2022 Mar;28(3):477-480
pubmed: 35046572
JAMA. 2022 Feb 15;327(7):639-651
pubmed: 35060999
Cell. 2022 Feb 3;185(3):447-456.e11
pubmed: 35026151
Nature. 2022 Feb;602(7898):664-670
pubmed: 35016195
Lancet. 2022 Feb 12;399(10325):625-626
pubmed: 35063123
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
N Engl J Med. 2022 Sep 8;387(10):953-954
pubmed: 36044619
Cell. 2022 Feb 3;185(3):467-484.e15
pubmed: 35081335
Clin Infect Dis. 2021 Dec 6;73(11):2065-2072
pubmed: 33906236
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Nature. 2022 Feb;602(7898):654-656
pubmed: 35016196
Nature. 2022 Feb;602(7898):682-688
pubmed: 35016197
Nature. 2022 Aug;608(7923):593-602
pubmed: 35714668
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288662
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
Nat Med. 2022 Mar;28(3):481-485
pubmed: 35051990
Nat Med. 2022 Sep;28(9):1785-1790
pubmed: 35760080
Age Ageing. 2022 May 1;51(5):
pubmed: 35595256
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288661
N Engl J Med. 2022 Mar 31;386(13):1207-1220
pubmed: 35172051
Nat Immunol. 2021 Nov;22(11):1428-1439
pubmed: 34471264
MMWR Morb Mortal Wkly Rep. 2022 Jul 22;71(29):931-939
pubmed: 35862287
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
J Travel Med. 2022 Sep 30;:
pubmed: 36179099
N Engl J Med. 2022 May 12;386(19):1804-1816
pubmed: 35263534
Sci Transl Med. 2020 Sep 2;12(559):
pubmed: 32817357
J Infect Dis. 2021 Sep 17;224(6):983-988
pubmed: 33693749
N Engl J Med. 2022 Jul 7;387(1):21-34
pubmed: 35704396
Lancet. 2022 Jan 29;399(10323):417-419
pubmed: 35065006
EMBO J. 2020 Dec 1;39(23):e106267
pubmed: 33051876
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059